Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ACAM3000 MVA Smallpox Vaccine
NCT00466245Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2005
- Primary completion
- Jun 2006
- Modality
- Viral Vector Vaccines
01
Overview
A Phase 2 trial of MVA3000 in smallpox, sponsored by Sanofi. Started Jul 2005; status: completed.
02
Drugs
MVA3000
03
Conditions
smallpox
Beyond the preview
Go deeper on NCT00466245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00466245.